Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BGM0504 Injection in Participants with Obesity or Overweight
Sponsor: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Official title: A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants with Overweight or Obese
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
620
Start Date
2024-10-28
Completion Date
2026-03-27
Last Updated
2024-11-26
Healthy Volunteers
No
Conditions
Interventions
5 mg BGM0504 injection
5mg BGM0504 injection administered subcutaneously (SC) once a week.
10 mg BGM0504 injection administered subcutaneously (SC) once a week
10mg BGM0504 injection administered subcutaneously (SC) once a week.
15 mg BGM0504 injection
15mg BGM0504 injection administered subcutaneously (SC) once a week.
BGM0504 placebo
BGM0504 placebo administered SC once a week.
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China